Nyrada

ASX Announcements


 
    Presentation to ASX Small and Mid-Cap Conference  
 
    Updated Share Trading Policy  
 
    Nyrada Reports Full Year FY2021 Results  
 
    Annual Report to 30 June 2021  
 
    Preliminary Final Report  
 
    Appendix 4G and Corporate Governance Statement  
 
    NYX-PCSK9i In Vivo Study Exploratory Analysis Results  
 
    Nyrada Announces US Patent Grant for PCSK9 Inhibitor  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - JM  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Confirmation of Capital Structure, CDIs on Issue  
 
    Notification regarding unquoted securities - NYR  
 
    Application for quotation of securities - NYR  
 
    Application for quotation of securities - NYR  
 
    NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction  
 
    Results of Meeting  
 
    Improved Drug Candidate Selected for WRAIR Studies  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Nyrada Receives A$1.0M R&D Tax Incentive Rebate  
 
    NYR Announces New Potent Cholesterol-Lowering Candidates  
 
    Change of Registered Office and Principal Place of Business  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    Change in substantial holding  
 
    Proposed issue of Securities - NYR  
 
    Nyrada Receives Firm Commitments to Raise A$11 Million  
 
    Nyrada Investor Presentation  
 
    Trading Halt  
 
    Change of Director's Interest Notice - JM  
 
    Nyrada Newsletter February 2021  
 
    Appendix 3G  
 
    Change of Director's Interest Notice - MF  
 
    Investor Presentation to Finance News Network CEO Showcase  
 
    Nyrada Reports Half Year FY2021 Results  
 
    Appendix 4D and Half Year Accounts  
 
    Lapsing of balance of Unlisted SAB Options  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    NYR Secures Collaboration with Walter Reed and UNSW  
 
    Trading Halt  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Reports Further Results from Cholesterol Study  
 
    Unlisted Scientific Advisory Board Options Expiry 15 Feb 21  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Release of Securities from Escrow  
 
    Change in substantial holding  
 
    57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study  
 
    Appointment of New Auditor  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - MF  
 
    Appendix 2A  
 
    Nyrada Annual General Meeting Results  
 
    Presentation to 2020 Annual General Meeting of Shareholders  
 
    Nyrada AGM 2020 Chairmans Address  
 
    Release of Securities from Escrow  
 
    Unlisted Convertible Note Options Expiring 30 November 2020  
 
    2020 Annual General Meeting Reminder  
 
    Letter to Shareholders and Proxy Form in relation to AGM  
 
    Notice of Annual General Meeting and Proxy Form  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Newsletter September 2020  
 
    Notification of Date of 2020 Annual General Meeting  
 
    Change of Director's Interest Notice - JM  
 
    Corporate Presentation for ShareCafe Hidden Gems Webinar  
 
    Nyrada Investor Webinar  
 
    Initial Director's Interest Notice - ID  
 
    Final Director's Interest Notice - GK  
 
    Annual Report to 30 June 2020  
 
    Appendix 4G and Corporate Governance Statement  
 
    FY 2020 Appendix 4E Preliminary Financial Report  
 
    Nyrada Board Changes  
 
    Nyrada Global Webcast Invitation  
 
    Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure  
 
    Nyrada Roadshow Corporate Presentation  
 
    Appendix 4C - June 2020 Quarterly Report  
 
    Nyrada Brain Injury Drug Pharmacokinetic Study Results  
 
    Nyrada Brain Injury Data Published by Premier US Military Health Conference  
 
    Change in substantial holding  
 
    Nyrada Cholesterol-Lowering Drug Study Results  
 
    Nyrada Newsletter June 2020  
 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Milestone Achieved in the Nyrada Brain Injury Program  
 
    Nyrada Preclinical Program & Corporate Update Presentation  
 
    Change of Director's Interest Notice - JM  
 
    Appointment of New Chief Financial Officer  
 
    Preclinical Program & Corporate Update Global Webinar  
 
    Appendix 4C - March 2020 quarterly  
 
    Nyrada Newsletter Released  
 
    Update on Progress in Nyrada Programs  
 
    Nyrada Inc. Corporate Presentation February 2020  
 
    Appendix 4D and Half Year Accounts  
 
    Significant advance in Nyrada PCSK9i program published  
 
    Nyrada Inc - Chairman's letter to shareholders  
 
    Becoming a substantial holder  
 
    Nyrada Inc - Corporate Presentation  
 
    NOX: Listing of Nyrada Inc. spin-off on ASX  
 
    NYR Commences Trading on the ASX  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Regulation S-Foreign Ownership Restrictions  
 
    Confirmation and Waiver under ASX Listing Rules  
 
    Pre-Quotation Disclosure  
 
    Updated Pro-forma - Financial Position and Commitments  
 
    Securities Trading Policy  
 
    Capital Structure and Restricted Securities  
 
    Financial Statements Year End 30 June 2019  
 
    Financial Statements Year End 30 June 2018  
 
    Corporate Governance Statement  
 
    Equity Incentive Plan  
 
    Amended and Restated Certificate of Incorporation and Bylaws  
 
    Supplementary Prospectus  
 
    Prospectus  
 
    Appendix 1A, Information Form and Checklist, Annexure 3  
 
    Distribution Schedule  
 
    Top 20 Securityholders  
 
    ASX Market Release - Admission and Quotation